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Nutritional epidemiology has an important role, as it can provide long-term data from large populations
and does not rely on surrogate markers for morbidity/mortality. Meaningful interpretation and appli-
cations of outcomes from epidemiological studies depend on the accurate assessment of dietary intake,
which is currently mainly based on a combination of self-reporting and food composition data.
Flavan-3-ols are a group of bioactives (non-essential dietary components with signiﬁcant impact on
health) that is a possible candidate for the development of dietary recommendations. The breadth of data
available on their effect on health also provides the basis for investigating the suitability of the methods
currently used in nutritional epidemiology to assess the health effects of bioactives. The outcomes of this
assessment demonstrate that the limitations of currently used methods make it virtually impossible to
estimate intake accurately from self-reported dietary data. This is due to the limitations of self-reporting,
especially from food-frequency questionnaires, and the inability of currently used methods to deal with
the high variability of food composition. Indeed, the estimated intake of ﬂavan-3-ols, can only be
interpreted as a marker of speciﬁc dietary patterns, but not as the actual intake amount.
The interpretation of results from such studies are fraught with serious limitations, especially for
establishing associations between intake and health and the development of dietary recommendations.
Alternative assessment not affected by these limitations, such as biomarkers, are required to overcome
these limitations. The development of nutritional biomarkers is therefore crucial to investigate the health
effect of bioactives.
© 2017 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Background and introduction
Lifestyle choices, such as smoking, physical activity and diet, are
important risk factors for CVD (Danaei et al., 2009; Ezzati and
Riboli, 2013) and therefore an important target for disease pre-
vention and health maintenance. In particular a low intake of plant-
based foods has been identiﬁed as key contributor to disease
burden (Lim et al., 2012), and this is reﬂected in dietary recom-
mendations and guidelines. Apart from those nutrients essential to
human life and procreation, plant-based foods contain phyto-
chemicals, so called bioactives, that while not essential to human
life, are proposed to affect human health by playing an important
role in health maintenance and disease risk reduction. Conse-
quently, there is an increasing interest in developing dietary rec-
ommendations and reference values (DRIs) for dietary bioactives
(Lupton et al., 2014). Key challenges in this context lie in estab-
lishing a common assessment framework for bioactives, such as it
exists for essential nutrients, including ways of establishingLtd. This is an open access articlecausality between the dietary intake of a given bioactive and
population-based measures of disease risk reduction or health
maintenance (Yetley et al., 2017; Food and Nutrition Board, The
National Academies of Sciences, Engineering and Medicine, 2017).1.1. Flavan-3-ols
Flavan-3-ols are a complex group of bioactives, consisting of
monomeric and polymeric compounds (Fig. 1). They have been
extensively investigated for their role in human health and nutri-
tion. Although the number of studies in this area is considerable,
most data currently available derive from small-to medium-scale,
short-term (weeks to several months) dietary intervention studies.
Such studies inevitably rely on the assessment of surrogate end-
points, such as measures of vascular function (Heiss et al., 2010b),
which inherently limits efforts aimed at translating study outcomes
into high-rigor impact assessments of disease risk reduction and
primary disease prevention (Weintraub et al., 2015; Bikdeli et al.,
2017). While available data are promising, there currently exists a
paucity of information from large-scale, long-term, randomised
trials withmortality ormorbidity outcomes. As a consequence, dataunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Structures of monomeric and polymeric ﬂavan-3-ols.
G.G.C. Kuhnle / Molecular Aspects of Medicine 61 (2018) 2e11 3from prospective epidemiological studies may provide information
on associations between long-term ﬂavan-3-ol intake and health
endpoints, despite of the well-known limitations regarding the
establishment of causality (Mayne et al., 2012; Yetley et al., 2017).
This review will focus on currently available data and evaluate
the strengths and limitations of nutritional epidemiology in
investigating potential associations between ﬂavan-3-ol intake and
cardiovascular diseases risk.2. Prospective epidemiological studies of ﬂavan-3-ols and
health
A key advantage of prospective cohort studies is that they can
provide long-term data for a large and diverse study populationand the opportunity to investigate temporal associations. They also
allow to investigate associations with disease risk, and do not
require the use of surrogate endpoints, thus providing a better
understanding of the association between intake and actual risk.
However, epidemiological studies also have several limitations, in
particular the vulnerability to confounding factors and difﬁculties
associated with accurate intake assessments. The latter is especially
crucial for the validity and applicability of outcome assessments
based on data derived from prospective epidemiological studies
(Yetley et al., 2017).
Inmost studies, ﬂavan-3-ol intake is assessed by combining self-
reported dietary information with data from food composition
databases. While this has been tacitly accepted as de facto standard,
it introduces a number of limitations that can affect outcomes and
G.G.C. Kuhnle / Molecular Aspects of Medicine 61 (2018) 2e114interpretations.
2.1. Assessment of dietary intake
2.1.1. Dietary sources
Flavan-3-ols are one of the most commonly consumed type of
ﬂavonoids (Otaki et al., 2009; Bai et al., 2014; Vogiatzoglou et al.,
2015b) and they are found in a wide range of different foods.
There are large regional differences between dietary sources. In
countries with a tea culture such as Japan, Australia or the UK, tea is
the main source of total ﬂavan-3-ol intake (Otaki et al., 2009;
Somerset and Johannot, 2008; Vogiatzoglou et al., 2015b),
whereas in other countries, themain sources are fruits, in particular
pome fruits (Vogiatzoglou et al., 2014). These differences also result
in a large variation of the type of ﬂavan-3-ol consumed. In countries
with high tea intake, these are in particular gallated ﬂavan-3-ols, as
well as theaﬂavins and thearubigins. Conversely, in countries
where the main sources are fruits and vegetables, the main types of
ﬂavan-3-ols consumed are proanthocyanidins and non-gallanted
monomers such as (e)-epicatechin. For example in the UK, where
tea is the main source of ﬂavan-3-ols, theaﬂavins and thearubigins
contribute more than half of total ﬂavan-3-ol intake, whereas in
Spain, where the main sources are fruits, the main contributor to
intake are proanthocyanidins whereas the intake of theaﬂavins and
thearubigins is negligible (Zamora-Ros et al., 2013; Vogiatzoglou
et al., 2014).
2.1.2. Self-reported dietary intake
The ideal dietary assessment method should be unbiased and
only introduce random error (Carroll et al., 2006; Keogh et al.,
2013), but such a method does not currently exist. Most studies
rely on self-reported information to estimate diet, and there are a
number of well-known limitations: they are prone to recall and
person-speciﬁc bias (Kipnis et al., 2001), can be affected by social
desirability (Hebert et al., 1995, 1997), and often results in speciﬁc
under- and over-reporting of foods (Freedman et al., 2014). This
affects especially those foods perceived to be healthy or unhealthy
(Bingham, 1997). These limitations and their impact on research
have been discussed extensively (Prentice et al., 2011; Subar et al.,
2015). Although methods have been developed to address these
shortcomings (Freedman et al., 2015), they have only been applied
to a small number of compounds and it is unknown whether they
are suitable for bioactives such as ﬂavan-3-ols. The dietary data
used in most studies is therefore based exclusively on self-
reporting, even though these methods have originally been
developed to assess dietary patterns and estimate the intake of
nutrients.
Semi-quantitative food-frequency questionnaires (FFQ) are the
most commonly used method, especially because they are rela-
tively easy to administer and inexpensive to process (Willett, 2013).
They use a limited selection of foods relevant to the target popu-
lation for which they were developed, and they require calibration
studies to estimate nutrient intake accurately (Carroll et al., 1997).
This introduces some constraints when applied to food substances,
such as bioactives, for which they were not originally designed:
1. Validation data show that FFQ-estimated intakes of individual
compounds such as micronutrients often correlate only
modestly with true intake (Jacques et al., 1993; Willett, 2013).
Data for isoﬂavones, the only ﬂavonoid group for which there
are detailed data, also show only weak correlations between
FFQ-estimated and true intake (Yamamoto et al., 2001; Heald
et al., 2006); notably this can be improved with FFQs devel-
oped to assess isoﬂavone intake (Frankenfeld et al., 2003; Tseng
et al., 2008). However, most FFQs currently used have neitherbeen designed speciﬁcally to assess ﬂavan-3-ol intake nor have
they been validated. It is therefore unknown how reliable the
estimates are that are derived via this approach.
2. Food items listed on FFQs are often grouped based on the dietary
habits of the target population and the original research ques-
tion in the context of which they were initially developed. This
often results in the combination of foods with wide ranges of
ﬂavan-3-ol content. For example, the EPIC Norfolk FFQ
(Mulligan et al., 2014) does not distinguish between red and
white wine, even though they differ considerably in both, ﬂa-
van-3-ol content (47 mg/100 mL vs 2 mg/100 mL) and compo-
sition (76% oligomeric proanthocyanidins in red wine vs
insigniﬁcant amounts in white wine). Similarly, the 2007 Har-
vard FFQ does not distinguish between apples (24 mg/100 g)
and pears (4 mg/100 g), and more importantly, between green
and black tea, which differ considerably in ﬂavan-3-ol content
and composition (monomeric compounds: 47 mg/100 mL vs 66
mg/100 mL; oligomeric compounds: 24 mg/100 mL vs 5 mg/
100 mL; Phenol-Explorer data (Rothwell et al., 2013),). While it
is possible to estimate population intake using weighed aver-
ages, this is not possible for individual participants of a study
and this approach is likely to result in considerable over- or
under-estimation of impact and introduces bias (Fig. 2).
Open-ended dietary assessment methods, such as diet diaries
(DD) or 24 h dietary recalls (24HDR), are not subject to the same
limitations as FFQs, but have not been used in many studies so far
(Table 1). However, they are still prone to similar biases, and more
importantly, like FFQs they have to rely on food composition data to
estimate ﬂavan-3-ol intake.
2.1.3. Food composition databases
As mentioned above, the actual intake of ﬂavan-3-ols, or any
other food substance, is estimated by combing data on food con-
sumption with food composition data. For ﬂavonoids, detailed da-
tabases have been compiled by the US Department of Agriculture
(USDA) (Bhagwat et al., 2004, 2014, 2015) and the Phenol Explorer
(Rothwell et al., 2013). The main limitation of this approach is the
large variability of food content, which is affected by numerous
factors such as variety, growth and harvest condition, storage, food
processing and others (Zamora-Ros et al., 2014). Indeed, it is likely
that food content varies even in fruits from the self-same plant
(Wilkinson and Perring, 1961). In black teas consumed in the UK,
ﬂavan-3-ol content varied more than 8-fold depending on variety
(Khokhar andMagnusdottir, 2002), and even larger variations were
found for green teas (Lin et al., 1998). Such large variability is also
found for other foods, for example apples (Sanoner et al., 1999;
Rothwell et al., 2013), and other potentially bioactive poly-
phenols, such as isoﬂavones (Kuhnle et al., 2009) or anthocyanidins
(Gao and Mazza, 1994) (Table 1).
This means that it is virtually impossible to estimate reliably
actual intake with methods relying on food composition data. Yet
the intake of ﬂavan-3-ols and many other ﬂavonoids is commonly
calculated using a single food content value, often based on small-
scale of food analyses. Moreover, there is a paucity of validated
analytical methods and many data were obtained before the
introduction of the AOAC methods (Machonis et al., 2014a, b). The
estimated intakes provided by previous studies should therefore be
regarded with great caution, and should perhaps best be inter-
preted as surrogate markers for speciﬁc dietary patterns, rather
than as accurate intake amounts for ﬂavan-3-ols. Methods devel-
oped to address measurement error from self-reporting, such as
regression calibration (Freedman et al., 2011), rely on a known and
consistent relationship between self-reported and actual intake.
However, it is not possible to estimate actual ﬂavan-3-ol content in
Fig. 2. Bias introduced by the low resolution of food items in FFQs. Estimated (e)-epicatechin intake based on self-reported consumption of two portions of wine, or two portions of
apples and pears. Data based on Phenol-Explorer and references therein. Data based on simulation of 100,000 participants choosing random combination of wine (two 250 mL
glasses of same wine) and two items of the Apple and Pear group. y Inter-quartile range; z based on the assumptions by Hooper et al. (2012) Clipart from Flaticon.
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to improve intake assessment.
In the absence of information on true intake, for example from
duplicate diet studies, the difference between true and estimatedintake is unknown. However, it is possible to assess the likely
impact of the difference using simulations. For the ﬂavan-3-ol
(e)-epicatechin, there exist detailed data regarding the range and
variability in the ﬂavan-3-ol content of foods commonly consumed
Table 1
Variability of ﬂavonoid content (by subclass) in foods commonly consumed (mean
and range in mg/100 g). Data based on Rothwell et al. (2013) and Kuhnle et al. (2009)
(isoﬂavones).
Food Compound Class Mean content Range
Blueberry (Highbush) Anthocyanidins 134 66e209
Strawberry Anthocyanidins 73 26e126
Wine (Red) Anthocyanidins 22 2e77
Onion (Red) Flavonols 128 58e394
Apple (Dessert) Flavan-3-ols 24 3e61
Black tea Flavan-3-ols 73 7e334
Green tea Flavan-3-ols 71 6e544
Chocolate (dark) Flavan-3-ols 153 77e273
Apple (Dessert) Isoﬂavones 8 5e10
Peas (frozen) Isoﬂavones 8 4e11
Savoy cabbage Isoﬂavones 3 1e6
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catechin intake estimated using two approaches: a) by using the
mean value of (e)-epicatechin food content applied to all partici-
pants (as is current practice), and b) by using for each participant a
random value within the reported range of the (e)-epicatechin
food content (see caption for details). Simulating the two ap-
proaches based on 25,000 people on a typical UK diet demonstrates
that there is only little agreement between the methods (Fig. 3).
The high variability in food content therefore does not only affect
the estimate of absolute intake, but also the ranking of intake and
subsequent assignment in quintiles. As quintiles are often used in
nutritional epidemiology to investigate associations between
intake and health endpoints, this is likely to have a considerable
impact on results.Fig. 3. Impact of food content variability on the classiﬁcation of participants into
quintiles of intake. Comparison of two approaches to estimate (e)-epicatechin intake:
a) using the mean food content for all participants as is current practice and, b) by
using a random value within the reported range of food content for each participant.
Figure is based on the simulation of 25,000 individuals consuming a typical UK diet
(National Diet and Nutrition Survey). Food content data are based on mean and range
information of the Phenol Explorer database (Rothwell et al., 2013). For approach b),
food content for each participant was determined using a normally distributed random
number within the given range.2.2. Interpretation of results
The associations between ﬂavan-3-ol intake and cardio-vascular
disease risk and risk markers have been investigated in numerous
epidemiological studies (Table 2), which found no or only modest
associations. However, all studies relied on self-reporting and food
composition database, and it is therefore questionable whether or
not the associations found can tenably be attributed to true dif-
ferences in ﬂavan-3-ol consumption. Indeed, it is likely that the
differences observed can only be attributed to speciﬁc dietary
patterns, for which estimated ﬂavan-3-ol intake is a surrogate
marker, but which so far have not been identiﬁed. In some in-
stances, estimated intake of ﬂavonoids is likely to be a surrogate
marker of social class, for example berries and tea (Song and Chun,
2008; Devore et al., 2012), which could help explain observed
beneﬁcial effects (Marmot, 2005).
2.3. Randomised controlled trials (RCT)
The advantage of dietary intervention studies over epidemio-
logical studies is usually the ability to deﬁne and characterise the
nature of the intervention. However, this is not always the case, and
for many studies only limited or no information on the actual
composition of the test products or test materials used in a given
dietary intervention were available. Whereas for some studies in
the context of polyphenol-related dietary interventions the test
products were well characterised using validated analytical
methods, others used the unspeciﬁc Folin-Ciocalteu assay (Folin
et al., 1915) and assumed that the only polyphenols present were
ﬂavan-3-ols, when in fact such assumptions cannot tenably be
made. Indeed, a recent analysis of intervention studies investi-
gating the effect of ﬂavan-3-ols derived from cocoa on cardio-
vascular disease risk found several studies, where the interven-
tionwas insufﬁciently characterised (Vlachojannis et al., 2016), and
Table 3 shows that many studies included in a recent Cochrane
review on the effects of cocoa intake on blood pressure (Ried et al.,
2017) provide only limited information about the intervention
used.
2.3.1. Intake-response relationship
There are large differences regarding the amount of details
provided about the type of dietary intervention used in RCTs. Dif-
ferences in the interpretation of ﬂavan-3-ol nomenclature and the
lack of standardised analytical methods to characterise the dietary
intervention make a comparison of studies very difﬁcult and often
impossible. This might explain the lack of reliable data on intake-
response relationships in meta-analyses. The recent Cochrane re-
view for example only investigates the effect of the intervention
without taking the amount or composition into consideration (Ried
et al., 2017). Other studies used different approaches to explore
intake-response relationships, such as the focusing exclusively on
(e)-epicatechin (Ellinger et al., 2012; Hooper et al., 2012) or using
total polyphenol intake (Shrime et al., 2011). These approaches
make assumptions about bioactive compounds and their mode of
action for which there are currently insufﬁcient data.
3. Outlook and conclusions
Results from smaller scale dietary intervention studies suggest
that ﬂavan-3-ol intake has a beneﬁcial effect on cardio-vascular
disease risk. Indeed, these compounds have been considered as a
possible candidate for DRI-like status due to their proposed bene-
ﬁcial effect on cardiovascular health (Williamson and Holst, 2008;
Schroeter et al., 2010; Lupton et al., 2014; Yetley et al., 2017).
However, the data supporting these beneﬁcial effects were derived
Table 2
Prospective epidemiological studies investigating associations between ﬂavan-3-ol intake and cardiovascular disease risk. Data shown are HR (95% CI) comparing bottom vs
top intake of ﬂavan-3-ols.
Study Population Dietary assesment method Endpoint Results (HR, 95% CI)
Mortality
Zutphen Elderly 806 men Diet history IHD 0.49 (0.27; 0.88) Arts et al. (2001)
Stroke 0.81 (0.36; 1.83)
IWHSa 34,489 women FFQ All-cause 0.98 (0.91; 1.06) Mink et al. (2007)
Stroke 0.95 (0.71; 1.28)
CHD 1.02 (0.86; 1.21)
CVD 0.95 (0.83; 1.09)
Kuopio Studya 2 682 men Food diary Ischaemic stroke 0.59 (0.30; 1.14) Mursu et al. (2008)
CVD 1.06 (0.64; 1.65)
CPS II 38,180 men FFQ CVD 0.87 (0.74; 1.04) McCullough et al. (2012)
60,289 women CVD 0.79 (0.66; 0.94)
EPIC Norfolka 11,252 men Food diary All-cause 0.99 (0.86; 1.14) Vogiatzoglou et al. (2015a)
CVD 0.95 (0.74; 1.20)
13,633 women All-cause 0.92 (0.78; 1.09)
CVD 0.81 (0.60; 1.09)
Incidence (nonfatal and fatal)
Zutphen Elderly 806 men Diet history Stroke 0.92 (0.51; 1.68) Arts et al. (2001)
MI 0.70 (0.39; 1.26)
NHS 69,622 women FFQ Ischaemic stroke 0.87 (0.72; 1.06) Cassidy et al. (2012)
NHS II 116,430 women FFQ MI 0.82 (0.61; 1.26) Cassidy et al. (2013)
EPIC Norfolka 11,252 men Food diary CVD 0.90 (0.81; 0.99) Vogiatzoglou et al. (2015a)
IHD 0.88 (0.77; 1.01)
Stroke 1.08 (0.82; 1.43)
13,633 women CVD 1.01 (0.91; 1.13)
IHD 0.96 (0.80; 1.17)
Stroke 0.89 (0.68; 1.19)
FHSOC 2 880 FFQ CVD 1.00 (0.88; 1.13)b Jacques et al. (2015)
a Indicates studies which included polymeric compounds.
b per 2e5 fold increase; IWHS: Iowa Women's Health Study; CPS: Cancer Prevention Study OO, NHS: Nurses Health Study; FHSOC: Framingham Heart Study Offspring
Cohort.
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markers, and often did not well-characterise the dietary in-
terventions used. The observed health beneﬁts therefore require
conﬁrmation at scale and greater rigor. In the context of developing
dietary recommendation, it is crucial to conduct long-term inter-
vention studies with disease endpoints and well characterised test
materials. In this context of ﬂavan-3-ol research, the currently
ongoing prospective dietary intervention trial COSMOS
(NCT02422745) aims at addressing several currently existing gaps.
Prospective epidemiological studies can also provide additional
information, in particular regarding the consumption of ﬂavan-3-
ols as part of the habitual diet. Such studies rely on the accurate
assessment of dietary intake, but the currently used methods,
which are almost exclusively based on self-reporting and food
composition databases, are highly limited or outright unsuitable.
While the limitations of self-reporting can often be overcome with
more sophisticated statistical methods, such an approach may not
be able to address a high variability in food content as it is not
predictable. These limitations are not restricted to ﬂavan-3-ols, but
also other phenolic compounds such as anthocyanidins, ﬂavones or
ﬂavanones where food content is also extremely variable.
Taken together, the estimated intake of ﬂavan-3-ols based on
current epidemiological studies should largely be interpreted as a
marker of speciﬁc dietary patterns, but not as the actual value for a
reasonably accurate intake amount. Often the results of epidemi-
ological studies are translated into dietary recommendations either
based on portion-sizes of speciﬁc foods or absolute intake amounts
of any given speciﬁc compound. However, this is currently not
possible for ﬂavan-3-ols, and likely many other bioactives. Conse-
quently, interpretations of currently available data from epidemi-
ological studies on the dietary intake of ﬂavan-3-ols, and other
bioactives, are fraught with serious limitations, especially forestablishing associations between intake and health, and thus in
the context of dietary recommendations.4. Future research priorities
For the reasons detailed above, it is important to develop
alternative methods for dietary assessment. Nutritional biomarkers
can provide reliable estimates of actual intake, not only for ﬂavan-
3-ols, but also of most other bioactive compounds (Jenab et al.,
2009; Zamora-Ros et al., 2012; Kuhnle, 2012). Their importance
has been recognised for more than two decades (Kaaks et al., 1997;
Food and Nutrition Board, The National Academies of Sciences,
Engineering and Medicine, 2017), but there is still a paucity of
well-characterised nutritional biomarkers and there are no
commonly agreed upon validation criteria. Some biomarkers have
been validated using extensive and large-scale dietary intervention
studies (Tasevska, 2015; Lampe et al., 2017) for individual nutrients,
others have used small-scale studies to develop biomarkers for
entire dietary patterns (Garcia-Perez et al., 2017), and many studies
have relied on self-reported intake as reference method.
The development of nutritional biomarkers requires an accurate
estimate of actual intake, which often can only be obtained from
duplicate diets. Moreover, it also requires a detailed understanding
of the pharmacokinetic properties of target compounds, as for
example, not all ﬂavan-3-ols are bioavailable and some are excreted
via the bile and not urine. A detailed understanding of metabolism
is also important as bioactives, in contrast to most micronutrients,
are xenobiotics and therefore extensively metabolise. Such data are
becoming more readily available, for example for (e)-epicatechin
(Ottaviani et al., 2016), and development of sensitive methods and
high-throughput analytical techniques has facilitated the applica-
tion of a biomarker-based approach to large cohort studies.
Table 3
Dietary intervention studies investigating the effect of ﬂavan-3-ols on systolic blood pressure.
Folina
mg/d
PF
mg/d
(e)-Epicatechin
mg/d
(þ)-Catechin
mg/d
PA
mg/d
DSBP (95% CI)
mmHg
Study
500 e 4 4 e 7.1 (11.4; 2.8) Al-Faris (2008)
e e 98 35 e 5.0 (10.8; 0.8) Baba et al. (2007)
500 305 25 13 267 0.3 (2.6; 3.2) van den Bogaard et al. (2010)
755 e e e e 0.5 (5.6; 4.6) Crews et al. (2008)
e 902 e e e 6.1 (12.9; 0.7) Davison et al. (2008)
e 902 e e e 1.6 (7.2; 10.4) Davison et al. (2008)
e 372 69 28 275 0.3 (6.0; 5.4) Davison et al. (2010)
e 1 052 208 58 785 4.4 (7.7; 1.1) Davison et al. (2010)
e 712 138 43 530 0.9 (2.4; 4.2) Davison et al. (2010)
e 520 95 35 390 5.5 (7.1; 3.9) Desideri et al. (2012)
e 993 185 62 746 10.0 (12.4; 7.6) Desideri et al. (2012)
e 168 e e 126 4.0 (7.1; 0.9) Fraga et al. (2005)
e 213 46 e e 1.8 (6.8; 10.4) Engler et al. (2004)
624 e 36 11 e 6.9 (14.0; 0.2) Flammer et al. (2012)
e e 66 22 e 6.5 (9.4; 3.6) Grassi et al. (2005)
e e 66 22 e 11.3 (13.3; 9.3) Grassi et al. (2005)
1 008 e 111 36 e 3.7 (5.1; 2.3) Grassi et al. (2008)
e 750 130 12 608 5.0 (11.3; 1.3) Heiss et al. (2010a)
e 900 128 14 754 0.0 (2.5; 2.5) Heiss et al. (2015)
e 900 128 14 754 4.0 (8.3; 0.3) Heiss et al. (2015)
645 414 15 153 134 1.0 (2.5; 4.5) Ibero-Baraibar et al. (2014)
e 495 10 46 426 3.0 (2.0; 8.0) Khan et al. (2012)
e 86 e e e 1.0 (2.3; 4.3) Koli (2015)
e 550 e e e 0.6 (6.9; 8.1) Shiina et al. (2009)
e 250 e e e 6.3 (3.3; 9.3) Massee et al. (2015)
e e 17 e e 0.0 (6.7; 6.7) Mellor et al. (2010)
e 400 e e e 0.8 (3.2; 1.6) Mogollon et al. (2013)
e 495 46 10 426 0.6 (6.8; 8.0) Monagas et al. (2009)
e 912 174 62 676 1.0 (4.1; 2.1) Muniyappa et al. (2008)
325 e e e e 0.0 (6.7; 6.7) Neuﬁngerl et al. (2013)
e 270 e e e 0.7 (1.1; 2.5) Nickols-Richardson et al. (2014)
e 234 e e e 1.0 (8.8; 6.8) Murphy et al. (2003)
e 805 48 21 736 3.2 (0.2; 6.6) Njike et al. (2011)
750 e e e e 2.9 (9.9; 15.7) Ried et al. (2009)
e 450 e e e 5.3 (7.6; 3.1) Rostami et al. (2015)
e 1 064 e e 841 1.0 (3.3; 1.3) Rull et al. (2015)
e 900 128 14 754 4.0 (6.5; 1.5) Sansone et al. (2015)
500 e 66 22 e 5.1 (6.1; 4.1) Taubert et al. (2003)
e e 5 2 e 3.0 (4.0; 2.1) Taubert et al. (2007)
e 494 89 21 384 2.8 (5.9; 0.3) Tzounis et al. (2011)
a Polyphenol content assessed using the Folin-Ciocalteau assay (Folin et al., 1915); PF: polyphenols; PA: proanthocyanidins, degree of polymerisation up to 10.
G.G.C. Kuhnle / Molecular Aspects of Medicine 61 (2018) 2e118The development, validation and application of biomarkers is
crucial for elucidating associations between intake of bioactives
and health outcomes. There are currently some limitations to the
development and application of nutritional biomarkers, and they
need to be addressed urgently. Most importantly is the develop-
ment of validation criteria, for example based on those suggested
by IARC (Kaaks et al., 1997), and the Institute of Medicine (Institute
of Medicine (US) Committee on Qualiﬁcation of Biomarkers and
Surrogate Endpoints in Chronic Disease et al., 2010). With the
increasing importance of high-quality data from epidemiological
studies for the development of dietary advice for the prevention
and maintenance of chronic diseases, the development of such
criteria is crucial.Appendix A. Supplementary data
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